A Multicenter, Double-blind, Placebo-controlled, Randomized Withdrawal, Parallel Group Study of Patiromer for the Management of Hyperkalemia in Subjects Receiving Renin-Angiotensin-Aldosterone System Inhibitor (RAASi) Medications for the Treatment of Heart Failure (DIAMOND)

Date Added
February 28th, 2020
PRO Number
Pro00097945
Researcher
Priya Kumar

List of Studies

Keywords
Heart
Summary

Prospective Phase 3b multinational, multicenter, double-blind, placebo-controlled,
randomized withdrawal, parallel group study that includes Screening and 12 weeks Run-in Phase (all subjects will have patiromer initiated and RAASi medications, including mineralocorticoid receptor antagonist (MRA), optimized) and a randomized withdrawal Blinded Treatment Phase.

Institution
Self Regional
Recruitment Contact
Alicia Shirley
864-943-2416
alicia.bryan-shirley@selfmedicalgroup.org



-- OR --